MaxCyte to Acquire Akron Bio, Expects to Nearly Double Revenue Base
MaxCyte says the acquisition will expand its cell therapy manufacturing offerings and expects to nearly double its revenue base.
Story updates
11:02:17 AM UTC
SquawkNews
MaxCyte agreed to acquire Akron Bio for $151.8M, including $105.0M cash, shares valued at approximately $26.8M and $20.0M in deferred payments. The deal is expected to close before year-end 2026 and is projected to nearly double MaxCyte’s revenue base; no prior-period comparison was provided.Materi…